Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Philips delivers Q4 sales of EUR 6.0 billion, with 7% comp. sales growth; income from cont. .
Royal PhilipsJanuary 25, 2021 GMT January 25, 2021 • Comparable order intake increased 7% • Income from continuing operations increased to EUR 608 million, compared to EUR 550 million in Q4 2019 • Adjusted EBITA margin increased to 19.0% of sales, compared to 17.9% of sales in Q4 2019 • Income from operations improved to EUR 795 million, compared to EUR 730 million in Q4 2019 • EPS from continuing operations (diluted) amounted to EUR 0.66; Adjusted EPS increased to EUR 0.94, compared to EUR 0.83 in Q4 2019 • Operating cash flow improved to EUR 1,305 million, compared to EUR 1,271 million in Q4 2019
January 25, 2021
5-year alliance will provide Vithas Group with state-of-the-art diagnostic imaging, image viewing solutions, and minimally-invasive intervention technology to deliver faster and more accurate diagnosis and treatment to patients
Vithas will become a ‘reference technology partner’ for Philips in Spain, giving it fast access to advances and innovations that Philips develops prior to their commercialization
New enterprise-wide network for diagnostic imaging will support unified working between more than 100 radiologists to facilitate workflow efficiency and research, as well as allowing patients to securely view their diagnostic reports and images on PCs and mobile devices
Amsterdam, the Netherlands and Madrid, Spain
–
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and
(2)
January 25, 2021
Two major randomized controlled trials (RCTs) show no difference in mortality between patients treated with the Philips Stellarex drug-coated balloon (DCB) and those treated with percutaneous angioplasty (PTA), the current standard of care
Amsterdam, the Netherlands -
Royal Philips).
The ILLUMENATE EU RCT and ILLUMENATE Pivotal RCT together comprised approximately 600 patients in Europe and the U.S. After five years, the ILLUMENATE EU RCT showed 19.3% mortality among patients treated with the Stellarex DCB compared to 19.4% mortality for those treated with PTA. The five-year results for the ILLUMENATE Pivotal study also show no statistically significant difference among patients treated with the Stellarex DCB (21.2%) compared to those treated with PTA (20.2%). Both studies had a high vital status follow-up compliance, with the status of over 90% of patients known.
• Comparable order intake increased 7%
• Income from continuing operations increased to EUR 608 million, compared to EUR 550 million in Q4 2019
• Adjusted EBITA margin increased to 19.0% of sales, compared to 17.9% of sales in Q4 2019
• Income from operations improved to EUR 795 million, compared to EUR 730 million in Q4 2019
• EPS from continuing operations (diluted) amounted to EUR 0.66; Adjusted EPS increased to EUR 0.94, compared to EUR 0.83 in Q4 2019
• Operating cash flow improved to EUR 1,305 million, compared to EUR 1,271 million in Q4 2019
• Free cash flow improved to EUR 1,055 million, compared to EUR 959 million in Q4 2019
Full-year highlights
• Comparable order intake increased 9%
• Income from continuing operations increased to EUR 1,205 million, compared to EUR 1,192 million in 2019
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Five-year ILLUMENATE EU RCT and Pivotal study results confirm safety profile of Philips .
Royal PhilipsJanuary 25, 2021 GMT
January 25, 2021
Two major randomized controlled trials (RCTs) show no difference in mortality between patients treated with the Philips Stellarex drug-coated balloon (DCB) and those treated with percutaneous angioplasty (PTA), the current standard of care
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the final, five-year results of two major randomized controlled trials (RCTs) that show no difference in all-cause mortality between patients treated with the Stellarex drug-coated balloon (DCB) and those treated with percutaneous angioplasty (PTA), the current standard of care. Moreover, the studies showed no difference in mortality between the Stellarex DCB and PTA at every 12-month endpoi